13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001493215
Total reported value
$11.7B
$11.7B
73 檔
18.0%
According to the latest 13F quarterly dataset, Rtw Investments, LP managed an equity portfolio of $11.7B at the end of Q2 2025, spanning 73 distinct U.S. exchange-listed positions.
In Q2 2025, Rtw Investments, LP displayed an active expansion posture, initiating 11 new positions and adding to 26 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 8.59% | -1.24% | — | |
| 2 | NTRA | Natera Inc | Stock-Healthcare | 6.24% | -0.17% | +0.00% | |
| 3 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 5.39% | +0.14% | +3.52% | |
| 4 | ARGX | Argenx Se - Adr | Stock-Healthcare | 5.29% | +0.46% | — | |
| 5 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 4.53% | -0.01% | +0.64% | |
| 6 | INSM | Insmed Inc | Stock-Healthcare | 4.42% | -3.47% | +2.32% | |
| 7 | AKRO | Akero Therapeutics Inc | Stock-Other | 4.16% | — | -26.17% | |
| 8 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.11% | — | +7.13% | |
| 9 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.89% | — | +9.97% | |
| 10 | SYK | Stryker CORP | Stock-Healthcare | 3.33% | -0.33% | EXIT | |
| 11 | PEN | Penumbra Inc | Stock-Healthcare | 3.16% | — | +0.09% | |
| 12 | ✓ | Merus N V | Stock-Other | 3.00% | — | -4.05% | |
| 13 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 2.76% | -0.04% | +5.33% | |
| 14 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 2.76% | -0.16% | +76.52% | |
| 15 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.26% | — | -48.10% | |
| 16 | RDNT | Radnet Inc | Stock-Healthcare | 2.18% | +0.17% | +16.08% | |
| 17 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 2.18% | -0.14% | — | |
| 18 | ALKS | Alkermes plc | Stock-Healthcare | 1.91% | +0.16% | -31.99% | |
| 19 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.90% | +0.43% | — | |
| 20 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.80% | -0.54% | -6.16% | |
| 21 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.68% | -2.33% | EXIT | |
| 22 | MASI* | Masimo CORP | Stock-Other | 1.64% | — | — | |
| 23 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.57% | +0.45% | +0.01% | |
| 24 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.57% | -1.01% | EXIT | |
| 25 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.28% | +0.30% | — | |
| 26 | DGX | Quest Diagnostics Inc | Stock-Healthcare | 1.28% | — | +405.07% | |
| 27 | QURE | uniQure N.V. | Stock-Other | 1.02% | +1.13% | +20.93% | |
| 28 | GHRS | GH Research PLC | Stock-Other | 0.96% | +0.53% | +0.74% | |
| 29 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.89% | +0.62% | +18.49% | |
| 30 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.88% | +1.46% | — | |
| 31 | ABT | Abbott Laboratories | Stock-Healthcare | 0.86% | — | — | |
| 32 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.83% | -0.25% | — | |
| 33 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.82% | +0.18% | +33.18% | |
| 34 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.77% | +1.13% | — | |
| 35 | BBNX | Beta Bionics Inc | Stock-Other | 0.68% | — | -0.02% | |
| 36 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.66% | — | +20.38% | |
| 37 | GH | Guardant Health Inc | Stock-Healthcare | 0.63% | +0.54% | — | |
| 38 | CGON | Cg Oncology Inc | Stock-Other | 0.63% | +0.46% | — | |
| 39 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.62% | -0.11% | — | |
| 40 | ✓ | Immatics NV | Stock-Other | 0.53% | -0.14% | +0.88% | |
| 41 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.51% | — | — | |
| 42 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.50% | — | — | |
| 43 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 0.36% | — | — | |
| 44 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.36% | — | — | |
| 45 | CMPS | Compass Pathways PLC | Stock-Other | 0.33% | +0.70% | +48.46% | |
| 46 | OBIO | Orchestra Biomed Holdings In | Stock-Other | 0.32% | — | +1.22% | |
| 47 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.31% | +1.55% | — | |
| 48 | NGNE | Neurogene Inc | Stock-Other | 0.29% | +0.10% | +1.02% | |
| 49 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.29% | -0.81% | EXIT | |
| 50 | ETNBGBP | 89bio Inc | Stock-Other | 0.28% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NBIX | Neurocrine Biosciences Inc | +1.9% | NEW | New buy |
| 2 | VRNA | Verona Pharma PLC - Adr | +1.3% | +7.13% | Add |
| 3 | ZLAB | Zai Lab Ltd-adr | +1% | +76.52% | Add |
| 4 | DGX | Quest Diagnostics Inc | +1% | +405.07% | Add |
| 5 | INSM | Insmed Inc | +0.9% | +2.32% | Add |
| 6 | ABT | Abbott Laboratories | +0.9% | NEW | New buy |
| 7 | NTRA | Natera Inc | +0.6% | +0.00% | Add |
| 8 | GH | Guardant Health Inc | +0.6% | NEW | New buy |
| 9 | ACAD | Acadia Pharmaceuticals Inc | +0.6% | +5.33% | Add |
| 10 | SLNOEUR | Soleno Therapeutics Inc | +0.5% | NEW | New buy |
| 11 | MLTX | Moonlake Immunotherapeutics | +0.5% | NEW | New buy |
| 12 | RDNT | Radnet Inc | +0.4% | +16.08% | Add |
| 13 | TSHA | Taysha Gene Therapies Inc | +0.4% | +33.18% | Add |
| 14 | QURE | uniQure N.V. | +0.3% | +20.93% | Add |
| 15 | ✓ | Merus N V | +0.3% | -4.05% | Trim |
| 16 | STOK | Stoke Therapeutics Inc | +0.3% | — | Unchanged |
| 17 | PTGX | Protagonist Therapeutics Inc | +0.3% | +0.64% | Add |
| 18 | 260 | Centessa Pharmaceuticals-adr | +0.3% | +2959.67% | Add |
| 19 | URGN | UroGen Pharma Ltd. | +0.2% | +18.49% | Add |
| 20 | JBIO | Jade Biosciences Inc | +0.2% | NEW | New buy |
| 21 | CRNX | Crinetics Pharmaceuticals In | +0.2% | NEW | New buy |
| 22 | RAPT | Rapt Therapeutics Inc | +0.2% | NEW | New buy |
| 23 | APGE | Apogee Therapeutics Inc | +0.1% | — | Unchanged |
| 24 | CTMX | Cytomx Therapeutics Inc | +0.1% | NEW | New buy |
| 25 | CMPS | Compass Pathways PLC | +0.1% | +48.46% | Add |
| 26 | XGN | Exagen Inc | +0.1% | +12.24% | Add |
| 27 | BBNX | Beta Bionics Inc | +0.1% | -0.02% | Trim |
| 28 | TEM | Tempus Ai Inc-cl A | +0.1% | — | Unchanged |
| 29 | ETNBGBP | 89bio Inc | +0.1% | — | Unchanged |
| 30 | ✓ | Immatics NV | +0.1% | +0.88% | Add |
| 31 | NGNE | Neurogene Inc | +0.1% | +1.02% | Add |
| 32 | OMDA | Omada Health Inc | +0.1% | NEW | New buy |
| 33 | ISRG | Intuitive Surgical Inc | 0% | — | Unchanged |
| 34 | MIST | Milestone Pharmaceuticals In | 0% | — | Unchanged |
| 35 | ✓ | Allurion Technologies Inc | 0% | +142.14% | Add |
| 36 | GHRS | GH Research PLC | 0% | +0.74% | Add |
| 37 | GEHC | GE Healthcare Technology | 0% | +20.38% | Add |
| 38 | LENZ | Lenz Therapeutics Inc | 0% | — | Unchanged |
| 39 | CRVS | Corvus Pharmaceuticals Inc | 0% | — | Unchanged |
| 40 | ORKA | Oruka Therapeutics Inc | — | — | Unchanged |
| 41 | VTLUSD | Immunic Inc | — | NEW | New buy |
| 42 | ADGM | Adagio Medical Holdings Inc | — | — | Unchanged |
| 43 | CBLL | Ceribell Inc | — | — | Unchanged |
| 44 | RCKTW | Rocket Pharmaceuticals In-27 | — | — | Unchanged |
| 45 | CGON | Cg Oncology Inc | 0% | — | Unchanged |
| 46 | TENX | Tenax Therapeutics Inc | 0% | — | Unchanged |
| 47 | ✓ | 0% | — | Unchanged | |
| 48 | CGEM | Cullinan Therapeutics Inc | 0% | — | Unchanged |
| 49 | SYK | Stryker CORP | 0% | +0.05% | Add |
| 50 | IMCR | Immunocore Holdings Plc-adr | 0% | — | Unchanged |
According to official SEC Form 13F filings, Rtw Investments, LP reported a total U.S. public equity portfolio value of $11.7B across 73 disclosed positions in Q2 2025.
During Q2 2025, Rtw Investments, LP's top holdings by market value included MDGL (8.6%)、NTRA (6.2%)、PTCT (5.4%). The largest single position, MDGL, represented 8.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MDGL, NTRA, PTCT) accounted for 18.0% of total reported equity market value during Q2 2025.
Top New Position Initiated
NBIX
市值: $133.5M
Top Position Liquidated / Trimmed
GMED
前期市值: $82.4M
In Q2 2025, Rtw Investments, LP made 50 total portfolio adjustments, initiating 11 new buys, adding to 26 positions, trimming 7 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.